Eur Rev Med Pharmacol Sci 2016; 20 (20): 4181-4182

Redefine staging of hepatocellular carcinoma on a “bench-to-bedside” approach

P. Magistri, G. Tarantino, A. Pecchi, R. Ballarin, F. Di Benedetto

Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy. paolo.magistri@uniroma1.it

Free PDF Download

To cite this article

P. Magistri, G. Tarantino, A. Pecchi, R. Ballarin, F. Di Benedetto
Redefine staging of hepatocellular carcinoma on a “bench-to-bedside” approach

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 20
Pages: 4181-4182

Keywords Related articles:

  1. A personalized approach identifies disturbed pathways and key genes in hepatitis C virus-cirrhosis with hepatocellular carcinoma
  2. Prognostic value of PUMA expression in patients with HBV-related hepatocellular carcinoma
  3. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology
  4. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma
  5. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein